Agile Therapeutics Inc (AGRX)

[mellow fellow]

week? 
10:40 AM EST, 12/09/2019 (MT Newswires) -- Agile Therapeutics (AGRX) provided an update on the phase 1 trial of cusatuzumab as a treatment for acute myeloid leukemia, in combination with azacytidine, according to a Monday filing.
All patients achieved a response, with 83% achieving either a complete response or incomplete hematologic recovery.
Four patients stayed in the study for at least a year while three patients were re-classified with risk category.
Upon the completion of the agreed terms for phase 1, Agile will receive a milestone payment of $25 million from Johnson & Johnson's (JNJ) Janssen affiliate.

Less